Trial Profile
Efficacy and safety of paritaprevir and ombitasvir in patients with chronic hepatitis C
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir (Primary) ; Paritaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2015 New trial record